Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials
New England Journal of Medicine · 24.09.2026 · 395 (12) · 1166-1179
DOI: 10.1056/nejmoa2601598 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 24.09.2026. Verfasst von Yves Dauvilliers und 38 weiteren Autor:innen. Beteiligte Einrichtung: Sleep-Wake Disorders Center, Department of Neurology, Gui-de-Chauliac Hospital, Centre Hospitalier Universitaire, Montpellier, France. Hauptthemen laut MEDLINE: Narcolepsy, Orexin Receptors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Takeda Development Center Americas.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sleep-Wake Disorders Center, Department of Neurology, Gui-de-Chauliac Hospital, Centre Hospitalier Universitaire, Montpellier, France.
- Institute for Neurosciences of Montpellier, INSERM, University of Montpellier, Montpellier, France.
- National Reference Network for Narcolepsy, Montpellier, France.
- Stanford Center for Sleep Sciences and Medicine, Palo Alto, CA.
- Department of Neurology, Jagiellonian University Medical College, Kraków, Poland.
- National Reference Center for Rare Hypersomnias, Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris.
Förderung
- Takeda Development Center Americas
Zitieren
APA
Dauvilliers, Y., Mignot, E., Antczak, J., Arnulf, I., Barateau, L., Buntinx, E., Corser, B., Iranzo, A., Khatami, R., Lammers, G. J., Lederer, K., Nilsen, K. B., Pizza, F., Schmidt, M. H., Sivam, S., Sum-Ping, O., Taniguchi, M., Zhan, S., Abraham, A., …, & The First Light and The Radiant Light (2026). Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials. New England Journal of Medicine, 395(12), 1166-1179. https://doi.org/10.1056/nejmoa2601598
Vancouver
Dauvilliers Y, Mignot E, Antczak J, Arnulf I, Barateau L, Buntinx E, et al. Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials. New England Journal of Medicine. 2026;395(12):1166-1179. doi:10.1056/nejmoa2601598
BibTeX
@article{Dauvilliers2026,
author = {Dauvilliers, Yves and Mignot, Emmanuel and Antczak, Jakub and Arnulf, Isabelle and Barateau, Lucie and Buntinx, Erik and Corser, Bruce and Iranzo, Alex and Khatami, Ramin and Lammers, Gert Jan and Lederer, Katharina and Nilsen, Kristian Bernhard and Pizza, Fabio and Schmidt, Markus H and Sivam, Sheila and Sum-Ping, Oliver and Taniguchi, Mitsutaka and Zhan, Shuqin and Abraham, Anson and Cai, Alice and Du, Yeting and Etherton, Mark R and Faessel, Helene and Hsiao, Samuel and Kadali, Harisha and Koundourakis, Elena and Naylor, Melissa and Neuwirth, Rachel and Olsson, Tina and Rogers, Raquel and Sheikh, Sarah and Tanaka, Shinichiro and von Rosenstiel, Philipp and von Hehn, Christian and Hang, Yaming and Yao, Baiyun and Del Rio Villegas, Rafael and Plazzi, Giuseppe and The First Light and The Radiant Light, The First Light and The Radiant Light},
title = {Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials},
journal = {New England Journal of Medicine},
year = {2026},
volume = {395},
number = {12},
pages = {1166--1179},
doi = {10.1056/nejmoa2601598}
}
EUVIMED